These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37212741)

  • 1. Supramolecular Filament Hydrogel as a Universal Immunomodulator Carrier for Immunotherapy Combinations.
    Wang F; Su H; Wang Z; Anderson CF; Sun X; Wang H; Laffont P; Hanes J; Cui H
    ACS Nano; 2023 Jun; 17(11):10651-10664. PubMed ID: 37212741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic supramolecular tubustecan hydrogel combined with checkpoint inhibitor elicits immunity to combat cancer.
    Wang F; Su H; Xu D; Monroe MK; Anderson CF; Zhang W; Oh R; Wang Z; Sun X; Wang H; Wan F; Cui H
    Biomaterials; 2021 Dec; 279():121182. PubMed ID: 34688987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydrogel-based co-delivery of CIK cells and oncolytic adenovirus armed with IL12 and IL15 for cancer immunotherapy.
    Du YN; Wei Q; Zhao LJ; Fan CQ; Guo LR; Ye JF; Li Y
    Biomed Pharmacother; 2022 Jul; 151():113110. PubMed ID: 35605298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Supramolecular assembly of a trivalent peptide hydrogel vaccine for cancer immunotherapy.
    Song H; Su Q; Nie Y; Zhang C; Huang P; Shi S; Liu Q; Wang W
    Acta Biomater; 2023 Mar; 158():535-546. PubMed ID: 36632876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Injectable polypeptide hydrogel-based co-delivery of vaccine and immune checkpoint inhibitors improves tumor immunotherapy.
    Song H; Yang P; Huang P; Zhang C; Kong D; Wang W
    Theranostics; 2019; 9(8):2299-2314. PubMed ID: 31149045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models.
    Rhode PR; Egan JO; Xu W; Hong H; Webb GM; Chen X; Liu B; Zhu X; Wen J; You L; Kong L; Edwards AC; Han K; Shi S; Alter S; Sacha JB; Jeng EK; Cai W; Wong HC
    Cancer Immunol Res; 2016 Jan; 4(1):49-60. PubMed ID: 26511282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATP-Responsive Smart Hydrogel Releasing Immune Adjuvant Synchronized with Repeated Chemotherapy or Radiotherapy to Boost Antitumor Immunity.
    Sun L; Shen F; Tian L; Tao H; Xiong Z; Xu J; Liu Z
    Adv Mater; 2021 May; 33(18):e2007910. PubMed ID: 33788339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prodrug hydrogel with tumor microenvironment and near-infrared light dual-responsive action for synergistic cancer immunotherapy.
    Ding M; Fan Y; Lv Y; Liu J; Yu N; Kong D; Sun H; Li J
    Acta Biomater; 2022 Sep; 149():334-346. PubMed ID: 35779775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
    Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Injectable Hydrogels as Local Depots at Tumor Sites for Antitumor Immunotherapy and Immune-Based Combination Therapy.
    Ma H; He C; Chen X
    Macromol Biosci; 2021 Jun; 21(6):e2100039. PubMed ID: 33818918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Photothermal therapy mediated by phase-transformation nanoparticles facilitates delivery of anti-PD1 antibody and synergizes with antitumor immunotherapy for melanoma.
    Zhang N; Song J; Liu Y; Liu M; Zhang L; Sheng D; Deng L; Yi H; Wu M; Zheng Y; Wang Z; Yang Z
    J Control Release; 2019 Jul; 306():15-28. PubMed ID: 31132380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapeutic effects of cytokine-induced killer cells combined with CCL21/IL15 armed oncolytic adenovirus in TERT-positive tumor cells.
    Ye JF; Lin YQ; Yu XH; Liu MY; Li Y
    Int Immunopharmacol; 2016 Sep; 38():460-7. PubMed ID: 27380620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programming Injectable DNA Hydrogels Yields Tumor Microenvironment-Activatable and Immune-Instructive Depots for Augmented Chemo-Immunotherapy.
    Fan Y; Zhan M; Liang J; Yang X; Zhang B; Shi X; Hu Y
    Adv Sci (Weinh); 2023 Oct; 10(29):e2302119. PubMed ID: 37541435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogel.
    Dai X; Meng J; Deng S; Zhang L; Wan C; Lu L; Huang J; Hu Y; Zhang Z; Li Y; Lovell JF; Wu G; Yang K; Jin H
    Theranostics; 2020; 10(7):3049-3063. PubMed ID: 32194854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel multifunctional anti-CEA-IL15 molecule displays potent antitumor activities.
    Liu Y; Wang Y; Xing J; Li Y; Liu J; Wang Z
    Drug Des Devel Ther; 2018; 12():2645-2654. PubMed ID: 30214153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydrogel-guided strategies to stimulate an effective immune response for vaccine-based cancer immunotherapy.
    Lei L; Huang D; Gao H; He B; Cao J; Peppas NA
    Sci Adv; 2022 Nov; 8(47):eadc8738. PubMed ID: 36427310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Supramolecular Tubustecan Hydrogel as Chemotherapeutic Carrier to Improve Tumor Penetration and Local Treatment Efficacy.
    Wang F; Su H; Lin R; Chakroun RW; Monroe MK; Wang Z; Porter M; Cui H
    ACS Nano; 2020 Aug; 14(8):10083-10094. PubMed ID: 32806082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optogenetic-controlled immunotherapeutic designer cells for post-surgical cancer immunotherapy.
    Yu Y; Wu X; Wang M; Liu W; Zhang L; Zhang Y; Hu Z; Zhou X; Jiang W; Zou Q; Cai F; Ye H
    Nat Commun; 2022 Oct; 13(1):6357. PubMed ID: 36289204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An injectable hydrogel using an immunomodulating gelator for amplified tumor immunotherapy by blocking the arginase pathway.
    Ren X; Wang N; Zhou Y; Song A; Jin G; Li Z; Luan Y
    Acta Biomater; 2021 Apr; 124():179-190. PubMed ID: 33524560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promoting the Recruitment, Engagement, and Reinvigoration of Effector T Cells via an Injectable Hydrogel with a Supramolecular Binding Capability for Cancer Immunotherapy.
    Zhu Y; Jin L; Chen J; Su M; Sun T; Yang X
    Adv Mater; 2023 Nov; 35(47):e2309667. PubMed ID: 37807931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.